Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 997 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inhibition Clear all
Completed Phase 1Phase 2 Interventional Results available

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

NCT04907214
View directory record Official record
Conditions
Obesity, Pre-diabetes
Interventions
Empagliflozin 25 MG
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 18, 2026, 10:29 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing the Reciprocal Inhibition Method and Post-isometric Inhibition Method of Muscle Energy Technique on the Spinal Reflex Excitability in Healthy Subjects

NCT03980106
View directory record Official record
Conditions
Relaxation; Joint, Limitation, Mobility, Relaxation; Lumbosacral
Interventions
Reciprocal Inhibition Muscle Energy Technique, Post-Isometric Inhibition Muscle Energy Technique
Other
Lead sponsor
University of North Georgia
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dahlonega, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Results available

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

NCT00454649
View directory record Official record
Conditions
Neoplasms
Interventions
Axitinib + Paclitaxel + Carboplatin (Cohort 1), Axitinib + Paclitaxel + Carboplatin (Cohort 2), Axitinib + Paclitaxel + Carboplatin (Cohort 3), Axitinib + Paclitaxel (Cohort 4), Axitinib + Docetaxel + Carboplatin (Cohort 4a), Axitinib + Docetaxel (Cohort 5), Axitinib + Capecitabine (Cohort 6), Axitinib + Capecitabine (Cohort 7), Axitinib + Gemcitabine + Cisplatin (Cohort 8), Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
10
States / cities
Augusta, Georgia • Harvey, Illinois • Tinley Park, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

NCT04425252
View directory record Official record
Conditions
COVID-19
Interventions
Brequinar, Standard of Care
Drug · Other
Lead sponsor
Clear Creek Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Hartford, Connecticut • Jacksonville, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

NCT05526911
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876, Midazolam, Digoxin
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Results available

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

NCT00561418
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer
Interventions
vorinostat, Correlative studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 18, 2026, 10:29 PM EDT
Not yet recruiting Phase 2 Interventional

Vascular Effects of SGLT2i in Non-diabetic CKD

NCT07060417
View directory record Official record
Conditions
Non-diabetic Chronic Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Early Phase 1 Interventional

RANKL Inhibition and Breast Tissue Biomarkers

NCT03629717
View directory record Official record
Conditions
Breast Cancer Prevention, Mammographic Density
Interventions
Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 4 Interventional

Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA

NCT00792233
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Withdrawal of anti-TNF therapy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 20 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fear Potentiation and Fear Inhibition in Posttraumatic Stress Disorder

NCT00209040
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Acoustic Startle Testing
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
425 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

NCT04040231
View directory record Official record
Conditions
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
Interventions
Galinpepimut-S, Nivolumab, Sargramostim
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

NCT00069160
View directory record Official record
Conditions
Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions
docetaxel, tariquidar, 99mTc-sestamibi imaging
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

NCT03930602
View directory record Official record
Conditions
Healthy
Interventions
BMS-986165, Fluvoxamine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 18, 2026, 10:29 PM EDT
Terminated Phase 4 Interventional

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

NCT00369603
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Razadyne ER, Aricept
Drug
Lead sponsor
Duke University
Other
Eligibility
40 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli

NCT05287724
View directory record Official record
Conditions
Pruritus, Skin Disorder
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

NCT00433966
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Bivalirudin, Unfractionated heparin, Bare metal stent, Paclitaxel-eluting stent
Drug · Device
Lead sponsor
Cardiovascular Research Foundation, New York
Other
Eligibility
18 Years and older
Enrollment
3,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 18, 2026, 10:29 PM EDT
Recruiting Not applicable Interventional

Mindfulness in Chronic Kidney Disease

NCT04099992
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Mindfulness-based stress reduction (MBSR), Health enhancement program (HEP), Transcutaneous Vagus Nerve Stimulation (tVNS), Sham-transcutaneous Vagus Nerve Stimulation (tVNS)
Behavioral · Device
Lead sponsor
Emory University
Other
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 18, 2026, 10:29 PM EDT
Withdrawn Phase 2 Interventional

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

NCT03005184
View directory record Official record
Conditions
Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 2 Interventional

Effect of Lithium and Divalproex in Alzheimer's Disease

NCT00088387
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Divalproex, Lithium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 10:29 PM EDT
Recruiting Phase 2 Interventional

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

NCT07783802
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

NCT01265953
View directory record Official record
Conditions
Prostate Cancer Prevention
Interventions
SFN-rich broccoli sprout extract capsules, Gelatin capsule containing microcrystalline cellulose.
Drug · Dietary Supplement
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
21 Years and older · Male only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 18, 2026, 10:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Surround Inhibition in Patients With Dystonia

NCT00029601
View directory record Official record
Conditions
Dystonic Disorders, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 10:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

NCT05256745
View directory record Official record
Conditions
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Interventions
TTP488, ddAC/ddT, TC, TCHP, Chemotherapy regimen that includes ddAC
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 18, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

NCT01187901
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Erlotinib, Sulindac, Placebo A, Placebo B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 69 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 18, 2026, 10:29 PM EDT